<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04953208</url>
  </required_header>
  <id_info>
    <org_study_id>388-20-HMO</org_study_id>
    <nct_id>NCT04953208</nct_id>
  </id_info>
  <brief_title>Remotely Non-invasive Brain Stimulation and Videogame to Alleviate Depression</brief_title>
  <official_title>The DiSCoVeR Project: Examining the Synergistic Effects of a Cognitive Control Videogame and a Self-administered Non-invasive Brain Stimulation on Alleviating Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mor Nahum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Riga Stradins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebrew University of Jerusalem</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder (MDD) is a common, recurrent, and frequent chronic disorder.&#xD;
      Treatment is often challenging; up to 40% of patients do not benefit sufficiently from&#xD;
      existing antidepressant interventions including trials of medication and psychotherapy. Up to&#xD;
      25% of patients manifest a chronic course of illness, resulting in a need for additional&#xD;
      treatment options.&#xD;
&#xD;
      The DiSCoVeR trial is a multi-site, double-blind, sham-controlled, proof-of concept&#xD;
      randomized controlled trial (RCT). The study aims to investigate the feasibility and efficacy&#xD;
      of an innovative, combined treatment approach, incorporating transcranial direct current&#xD;
      stimulation (tDCS) along with a custom-made video game designed to enhance cognitive control&#xD;
      in patients with major depressive disorder (MDD).&#xD;
&#xD;
      Patients diagnosis of MDD receive a 6-weeks treatment with prefrontal tDCS along with an&#xD;
      active videogame or sham tDCS + sham game for 6 weeks. Follow-up per patient is 6 weeks&#xD;
      following treatment. Before, during and after the treatment period different assessment&#xD;
      scales will be conducted to record neuropsychological features and the course of symptom&#xD;
      changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major Depressive Disorder (MDD) is a prevalent, seriously impairing, and often recurrent&#xD;
      mental disorder. It has been ranked as a leading cause of disability worldwide by the World&#xD;
      Health Organization (WHO) as measured by years lived with disability.&#xD;
&#xD;
      A considerable number of patients with MDD experience a chronic course of illness and&#xD;
      approximately one third of MDD patients do not respond sufficiently to pharmacological&#xD;
      treatment, calling for treatment alternatives.&#xD;
&#xD;
      Non-invasive brain stimulation techniques (NIBS) such as tDCS targeting prefrontal cortical&#xD;
      areas have emerged as a safe, promising, and cost-effective alternative to traditional&#xD;
      treatment options in patients with MDD.&#xD;
&#xD;
      This study focuses not only on an overall reduction of depressive symptoms, but also an&#xD;
      alleviation of cognitive control deficits in particular, since patients with MDD often suffer&#xD;
      from cognitive control deficits. tDCS has been shown to directly modulate cognitive control&#xD;
      functions in healthy participants and in depressed patients. Another approach to directly&#xD;
      modulate cognitive control functions is cognitive control training.&#xD;
&#xD;
      In the present study, an engaging and captivating cognitive control training designed as an&#xD;
      action video game will be employed. The primary objective is to test the feasibility and&#xD;
      efficacy of this innovative, combined treatment approach for self application, concurrently&#xD;
      applying both interventions (tDCS + cognitive control training) in patients suffering from&#xD;
      MDD. Additionally, participants have the opportunity to choose to take part in two adjunctive&#xD;
      assessments: a biological assessment which includes salivary samples and a multimodal imaging&#xD;
      paradigm (fMRI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of treatment</measure>
    <time_frame>Six weeks</time_frame>
    <description>Feasibility is met if a patient will complete 20 sessions per protocol with a probability of more than 50.00%.Completion per protocol is achieved, if the patient completes 20 sessions per protocol with a probability of more than 50 percent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy-Improvement on the MADRS scores compared to baseline.</measure>
    <time_frame>six weeks</time_frame>
    <description>Change from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) scores at week 6 post-randomization compared to baseline.&#xD;
The MADRS scores severity of depression on a scale from 0-60. Higher scores indicate worse depression. A total score between 0-6 indicates that the patient is in the normal range (no depression), 7-19 indicates mild depression, 20-34 indicates moderate depression, and a score of 35 and greater indicates severe depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active tDCS (using the Neuroelectrics Starstim tCS 5G kit) and cognitive and emotional control video game</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>sham tDCS (using the Neuroelectrics Starstim tCS 5G kit) and non-active videogame</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>active tDCS</intervention_name>
    <description>Treatment will be applied daily 5 days/week for a period of 6 weeks, which equals a tDCS stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham tDCS</intervention_name>
    <description>sham stimulation for a total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.</description>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>cognitive and emotional control video game</intervention_name>
    <description>a video game targeting cognitive and emotional control. total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>sham video game</intervention_name>
    <description>a video game which does not target cognitive control, played for total of 30 treatment sessions. Every treatment session consists of 30 minutes of intervention.</description>
    <arm_group_label>Sham treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Men and woman 18-65 years of age.&#xD;
&#xD;
          -  Primary Diagnostic and Statistical Manual (DSM-5) diagnosis of Major Depressive&#xD;
             Disorder (MDD), with a single or recurrent episode with the additional requirement of&#xD;
             a current episode with a duration of ≥4 weeks.&#xD;
&#xD;
          -  Current depressive episode lasts less than 5 years (the current and previous&#xD;
             depressive episodes are demarcated by a period of ≥2 months in which the patient did&#xD;
             not meet full criteria for the DSM-5 definition of MDD).&#xD;
&#xD;
          -  Total Hamilton-21 score ≥ 13 at screening visit.&#xD;
&#xD;
          -  Capable and willing to provide informed consent. Patients without antidepressant&#xD;
             medication or patients on an adequate (i.e., at least lowest effective) and stable&#xD;
             (i.e., for ≥ 6 weeks) dosage of SSRI (Escitalopram, Citalopram, Sertralin, Paroxetin,&#xD;
             Fluvoxamin, Fluoxetin), SSNRI (Duloxetin, Venlafaxin) or Others (Mirtazapin,&#xD;
             Agomelatin, Vortioxetine)&#xD;
&#xD;
          -  Concomitant psychotherapy is allowed if ongoing for at least 3 months prior to&#xD;
             baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigators, site personnel directly affiliated with this study, and their immediate&#xD;
             families (immediate family is defined as a spouse, parent, child or sibling, whether&#xD;
             by birth or legal adoption).&#xD;
&#xD;
          -  Addiction to gaming as assessed by the Gaming Disorder Test (GDT).&#xD;
&#xD;
          -  Individuals diagnosed with the following psychiatric conditions (current unless&#xD;
             otherwise stated):&#xD;
&#xD;
               -  Depression assessed as secondary to a general medical condition or&#xD;
                  substance-induced&#xD;
&#xD;
               -  Substance abuse or substance dependence (except nicotine, caffeine) in the last 6&#xD;
                  months&#xD;
&#xD;
               -  Psychotic disorder (lifetime)&#xD;
&#xD;
               -  Bipolar disorder (I and II; lifetime)&#xD;
&#xD;
               -  Eating disorder if stated as primary diagnosis&#xD;
&#xD;
               -  Obsessive compulsive disorder if stated as primary diagnosis&#xD;
&#xD;
               -  Post-traumatic stress disorder if stated as primary diagnosis&#xD;
&#xD;
               -  Generalized anxiety disorder if stated as primary diagnosis&#xD;
&#xD;
               -  Panic disorder/ social anxiety if stated as primary diagnosis&#xD;
&#xD;
               -  Personality disorder if stated as primary diagnosis&#xD;
&#xD;
          -  Individuals diagnosed with a significant neurological disorder or insult including,&#xD;
             but not limited to:&#xD;
&#xD;
               -  Increased intracranial pressure&#xD;
&#xD;
               -  Space occupying brain lesion&#xD;
&#xD;
               -  History of cerebrovascular accident&#xD;
&#xD;
               -  Transient ischemic attack within two years&#xD;
&#xD;
               -  Cerebral aneurysm, dementia&#xD;
&#xD;
               -  Parkinson's disease&#xD;
&#xD;
               -  Huntington's chorea&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Epilepsy&#xD;
&#xD;
          -  Electroconvulsive therapy (ECT) treatment in current episode&#xD;
&#xD;
          -  History of tDCS, except for single tDCS sessions in experimental studies&#xD;
&#xD;
          -  Use of any investigational drug within 6 weeks from baseline&#xD;
&#xD;
          -  Suicidal risk based on MADRS item 10 score of 4-6 or attempted suicide in current&#xD;
             episode&#xD;
&#xD;
          -  Acute, unstable cardiac disease&#xD;
&#xD;
          -  Intracranial implant or any other metal object within or near the head (excluding the&#xD;
             mouth) that cannot be safely removed; implanted neuro-stimulators&#xD;
&#xD;
          -  Known or suspected pregnancy (according to pregnancy test), and women of childbearing&#xD;
             potential not using effective contraception&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Treatment with deep brain stimulation or vagus nerve stimulation and/or any other&#xD;
             intracranial implants (clips, cochlear implants)&#xD;
&#xD;
          -  Any relevant unstable medical condition (e.g. acute, unstable cardiac disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mor Nahum, PhD</last_name>
    <phone>0547326655</phone>
    <email>mor.nahum@mail.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Omer Bonne, Professor Medical Doctor</last_name>
    <email>bonne@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ludwig-Maximilian University</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Dechantsreiter</last_name>
      <email>Esther.Dechantsreiter@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Frank Padberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>12000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alon Morash</last_name>
      <email>alonmorash@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Omer Bonne, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riga Stradins University (RSU)</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Rubene, M.D.</last_name>
      <email>lindarubene93@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elmars Rancans, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Latvia</country>
  </location_countries>
  <results_reference>
    <citation>Padberg F, Bulubas L, Mizutani-Tiebel Y, Burkhardt G, Kranz GS, Koutsouleris N, Kambeitz J, Hasan A, Takahashi S, Keeser D, Goerigk S, Brunoni AR. The intervention, the patient and the illness - Personalizing non-invasive brain stimulation in psychiatry. Exp Neurol. 2021 Jul;341:113713. doi: 10.1016/j.expneurol.2021.113713. Epub 2021 Mar 31. Review.</citation>
    <PMID>33798562</PMID>
  </results_reference>
  <results_reference>
    <citation>Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 Mar 23;354(12):1231-42.</citation>
    <PMID>16554525</PMID>
  </results_reference>
  <results_reference>
    <citation>Brunoni AR, Moffa AH, Sampaio-Junior B, Borrione L, Moreno ML, Fernandes RA, Veronezi BP, Nogueira BS, Aparicio LVM, Razza LB, Chamorro R, Tort LC, Fraguas R, Lotufo PA, Gattaz WF, Fregni F, Benseñor IM; ELECT-TDCS Investigators. Trial of Electrical Direct-Current Therapy versus Escitalopram for Depression. N Engl J Med. 2017 Jun 29;376(26):2523-2533. doi: 10.1056/NEJMoa1612999.</citation>
    <PMID>28657871</PMID>
  </results_reference>
  <results_reference>
    <citation>Padberg F, Kumpf U, Mansmann U, Palm U, Plewnia C, Langguth B, Zwanzger P, Fallgatter A, Nolden J, Burger M, Keeser D, Rupprecht R, Falkai P, Hasan A, Egert S, Bajbouj M. Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC). Eur Arch Psychiatry Clin Neurosci. 2017 Dec;267(8):751-766. doi: 10.1007/s00406-017-0769-y. Epub 2017 Feb 28.</citation>
    <PMID>28246891</PMID>
  </results_reference>
  <results_reference>
    <citation>De Raedt R, Koster EH. Understanding vulnerability for depression from a cognitive neuroscience perspective: A reappraisal of attentional factors and a new conceptual framework. Cogn Affect Behav Neurosci. 2010 Mar;10(1):50-70. doi: 10.3758/CABN.10.1.50. Review.</citation>
    <PMID>20233955</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolkenstein L, Plewnia C. Amelioration of cognitive control in depression by transcranial direct current stimulation. Biol Psychiatry. 2013 Apr 1;73(7):646-51. doi: 10.1016/j.biopsych.2012.10.010. Epub 2012 Dec 6.</citation>
    <PMID>23219367</PMID>
  </results_reference>
  <results_reference>
    <citation>Calkins AW, McMorran KE, Siegle GJ, Otto MW. The Effects of Computerized Cognitive Control Training on Community Adults with Depressed Mood. Behav Cogn Psychother. 2015 Sep;43(5):578-89. doi: 10.1017/S1352465814000046. Epub 2014 Mar 3.</citation>
    <PMID>24589123</PMID>
  </results_reference>
  <results_reference>
    <citation>Bavelier D, Green CS. Enhancing Attentional Control: Lessons from Action Video Games. Neuron. 2019 Oct 9;104(1):147-163. doi: 10.1016/j.neuron.2019.09.031. Review.</citation>
    <PMID>31600511</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoorelbeke K, Koster EHW. Internet-delivered cognitive control training as a preventive intervention for remitted depressed patients: Evidence from a double-blind randomized controlled trial study. J Consult Clin Psychol. 2017 Feb;85(2):135-146. doi: 10.1037/ccp0000128. Epub 2016 Jun 30.</citation>
    <PMID>27362792</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebrew University of Jerusalem</investigator_affiliation>
    <investigator_full_name>Mor Nahum</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cognitive control</keyword>
  <keyword>non-invasive brain stimulation, transcranial direct current stimulation</keyword>
  <keyword>VideoGame</keyword>
  <keyword>self-application</keyword>
  <keyword>home-based</keyword>
  <keyword>feasibility</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

